Saturday, March 28, 2015
   
TEXT_SIZE

The Stock Alerts Featured Profiles

image image image image
Matinas BioPharma Holdings, Inc Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) , is a clinical-stage biopharmaceutical company, founded in 2011, with a focus on identifying and developing novel lipid-based pharmaceutical products for the treatment cardiovascular and metabolic conditions and infectious diseases. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas is focused on creating highly differentiated, safe and efficacious therapies utilizing its expertise in drug formulation and development.
HydroPhi Technologies Group, Inc.   HydroPhi Technologies Group, Inc. (OTCQB: HPTG) is a developer of water-based hydrogen fuel production systems. The Company's technology isn't a fuel cell, nor is it a hydrogen alternative to traditional hydrocarbon fuels. The system utilizes distilled water for the production of hydrogen and oxygen, which is then injected into the air intake of an engine utilizing carbon-based fuels such as diesel, unleaded gasoline and natural gas. HPTG's technology, (HydroPlant™) has been company tested with resulting reduced vehicle operating costs by improved fuel efficiency up to 20%, while lowering greenhouse gas emissions up to 70%.
Axxess Pharma, Inc. Axxess Pharma, Inc. (Pinksheets: AXXE) Axxess Pharma, Inc. is a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products in niche markets. Although they serve the General Practice market, Axxess Pharma, Inc. also distributes products that target Dermatology, Rheumatology, Gynecology, Urology and Nephrology markets. Axxess Pharma also hold global license rights to high demand all natural TapouT products.
PharmaCyte Biotech, Inc. PharmaCyte Biotech, Inc. (OTCQB: PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form.
Move
-

Stock Screens

Top Headline

This week, the world's most powerful leaders — the Group of Eight — met in Italy to discuss how to handle the global recession. Meanwhile, oil prices plunged, ousted Honduran president Manuel Zelaya tried to regain power of his country and violent protests broke out in China. Those events aren't the only reasons why the international scene is getting its fair share of the spotlight. Indeed, just as attention-grabbing: fund performance. According to Lipper, the average domestic equity...

Read More...

Ten days from now, Sioux City, Iowa, will reach a high of 83 degrees Fahrenheit. At least, that's what I'm estimating. I’m not a trained meteorologist. But then, according to accuracy-tracker ForecastWatch, predictions for more than nine days out tend to be less reliable than simply assuming that date’s weather will match its 30-year average, as I’ve done for Sioux City. Still, weather forecasters are vastly more reliable than Wall Street analysts when the latter are announcing...

Read More...

Investors have returned to stocks in brave fashion. But while they're placing pricey bets on struggling sectors, they may be ignoring some prosperous and cheap companies whose products fill their kitchen pantry. Since the S&P 500 index closed at a humble 676 on March 9 it has rebounded 30%. Within the index, financials and “consumer discretionary” companies — the latter sell things we want but don’t need, like toys and restaurant meals — have soared 83% and 37%,...

Read More...

Growth is scarce at the moment. The average of America’s 500 largest companies saw its sales shrink 8% in its last reported quarter. Yet investors seem willing to pay high prices for shares. The S&P 500 trades at 16 times forecast 2009 earnings (a projection which assumes earnings will rise 12% this year). How that compares with the long history of stocks, we can’t say, since consensus estimates and forward price/earnings ratios weren’t always available, but the index has...

Read More...

Companies don't seem interested in buying rivals at the moment, despite the comparatively low prices they could pay for them. That bodes poorly for stocks in general, but investors can still use the math of takeover pros to find bargains. U.S. shares are 27% cheaper than a year ago, even after climbing 15% in the second quarter. During the first half, though, the value of announced acquisitions in the U.S. fell 45% from a year earlier, according to data provider Dealogic. TrimTabs, an investment...

Read More...

Stock Ticker

Trade Alerts

Please make the Cache directory writable.

Visit us on Twitter

twitter_logo

1 DOW 17,712.66
+34.43 (0.19%)    
2 S&P 2,061.02
+4.87 (0.24%)    
3 NASDAQ 4,891.22
+27.86 (0.57%)    

Login Form